D van der Heijde Selected Research

Antirheumatic Agents (DMARD)

1/2017	Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.
1/2012	European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies.
7/2011	Favorable effect of very early disease-modifying antirheumatic drug treatment on radiographic progression in early inflammatory arthritis: Data from the Étude et Suivi des polyarthrites indifférenciées récentes (study and followup of early undifferentiated polyarthritis).
1/2011	Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register.
12/2009	ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis.
4/2009	Remission achieved after 2 years treatment with low-dose prednisolone in addition to disease-modifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years: an open 2-year continuation study.
1/2009	Factors determining a DMARD initiation in early inflammatory arthritis patients. The ESPOIR cohort study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

D van der Heijde Research Topics

Disease

33	Ankylosing Spondylitis 01/2019 - 07/2000
25	Rheumatoid Arthritis 01/2017 - 04/2001
17	Necrosis 03/2016 - 09/2002
12	Back Pain (Backache) 01/2015 - 05/2004
11	Psoriatic Arthritis 01/2017 - 08/2006
11	Arthritis (Polyarthritis) 09/2014 - 09/2000
10	Axial Spondyloarthritis 06/2017 - 06/2009
10	Inflammation (Inflammations) 04/2016 - 09/2002
9	Pain (Aches) 12/2018 - 01/2001
7	Rheumatic Diseases (Rheumatism) 03/2016 - 03/2005
7	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2015 - 05/2004
5	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 09/2014 - 05/2004
5	Sacroiliitis 09/2014 - 05/2004
3	Disease Progression 04/2016 - 06/2004
3	Infections 01/2014 - 09/2000
3	Spondylarthropathies 11/2005 - 09/2000
2	Synovitis 04/2016 - 10/2009
2	Osteoarthritis 04/2016 - 11/2000
2	Uveitis 01/2016 - 01/2011
2	Anterior Uveitis 09/2014 - 05/2004
2	Reactive Arthritis (Reiter Disease) 09/2000 - 07/2000
1	Spondylitis 09/2014
1	Opportunistic Infections (Opportunistic Infection) 01/2014
1	Neoplasms (Cancer) 01/2014
1	Non-Radiographic Axial Spondyloarthritis 01/2014
1	Tenosynovitis 10/2009
1	Rheumatoid Nodule 11/2008
1	Ankylosis 09/2008
1	Spinal Diseases (Disease, Spinal) 04/2008
1	Ulcerative Colitis 05/2007
1	Crohn Disease (Crohn's Disease) 05/2007
1	Joint Diseases (Joint Disease) 05/2006
1	Fibromyalgia (Fibrositis) 03/2005
1	Acquired Immunodeficiency Syndrome (AIDS) 03/2005
1	Fatigue 01/2005

Drug/Important Bio-Agent (IBA)

13	Methotrexate (Mexate)FDA LinkGeneric 01/2017 - 04/2004
12	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2017 - 09/2002
11	Etanercept (Enbrel)FDA Link 01/2014 - 09/2002
10	Certolizumab Pegol FDA Link 01/2017 - 06/2009
10	Infliximab (Remicade)FDA Link 02/2009 - 09/2002
8	O,O-diisopropyl-S-benzylthiophosphate (IBP)IBA 01/2015 - 05/2004
7	C-Reactive ProteinIBA 01/2017 - 11/2004
7	Antirheumatic Agents (DMARD)IBA 01/2017 - 01/2009
6	Tumor Necrosis Factor InhibitorsIBA 03/2016 - 04/2008
6	AntibodiesIBA 01/2016 - 09/2000
5	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2019 - 08/2001
5	HLA-B27 Antigen (HLA B27 Antigen)IBA 06/2017 - 07/2000
4	ametantrone (HAQ)IBA 01/2015 - 01/2005
4	Sulfasalazine (Azulfidine)FDA LinkGeneric 01/2014 - 09/2003
4	Biomarkers (Surrogate Marker)IBA 01/2010 - 04/2008
3	Gadolinium DTPA (Magnevist)FDA Link 03/2014 - 11/2002
3	GadoliniumIBA 03/2014 - 09/2002
3	cyclic citrullinated peptideIBA 01/2010 - 02/2008
3	SteroidsIBA 07/2009 - 09/2003
3	amsonic acid (DAS)IBA 02/2008 - 11/2005
2	AntigensIBA 01/2011 - 03/2008
2	Anti-Citrullinated Protein AntibodiesIBA 02/2010 - 01/2010
2	Rheumatoid FactorIBA 01/2010 - 11/2008
2	Immunoglobulin A (IgA)IBA 01/2010 - 11/2008
2	Immunoglobulin M (IgM)IBA 01/2010 - 11/2008
2	Proteins (Proteins, Gene)FDA Link 01/2010 - 02/2009
2	Adalimumab (Humira)FDA Link 06/2009 - 09/2008
2	EpitopesIBA 02/2009 - 11/2008
2	Immunoglobulin G (IgG)IBA 02/2009 - 03/2008
2	Protein-Arginine DeiminasesIBA 02/2009 - 03/2008
2	TEMPOIBA 12/2007 - 03/2006
2	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 11/2005 - 11/2000
2	Contrast MediaIBA 11/2002 - 09/2002
1	secukinumabIBA 01/2019
1	4-hexyloxyaniline (HOA)IBA 04/2016
1	golimumab FDA Link 10/2015
1	Inosine Monophosphate (IMP)IBA 09/2014
1	acetyl 4-aminosalicylic acidIBA 02/2010
1	VimentinIBA 02/2010
1	Leukocyte L1 Antigen Complex (Calgranulin)IBA 01/2010
1	Folic Acid (Vitamin M)FDA LinkGeneric 07/2009
1	GlucocorticoidsIBA 04/2009
1	Prednisolone (Predate)FDA LinkGeneric 04/2009
1	HLA-DRB1 Chains (HLA DRB1)IBA 11/2008
1	AutoantibodiesIBA 11/2008
1	theasinensin AIBA 09/2008
1	Interleukin-6 (Interleukin 6)IBA 04/2008
1	Aligeron (AS 2)IBA 12/2006
1	EtoricoxibIBA 11/2005
1	Naproxen (Naprosyn)FDA LinkGeneric 11/2005
1	Leflunomide (Arava)FDA LinkGeneric 06/2004
1	Acute-Phase Proteins (Acute-Phase Protein)IBA 09/2003
1	Pentetic Acid (DTPA)FDA LinkGeneric 09/2002

Therapy/Procedure

23	Therapeutics 01/2017 - 04/2001
3	Aftercare (After-Treatment) 04/2008 - 05/2004
2	Contraindications 03/2006 - 09/2003
2	Biological Therapy 03/2005 - 09/2003
1	Activities of Daily Living (ADL) 12/2018
1	Replacement Arthroplasty 12/2009
1	Perioperative Period 07/2009
1	Withholding Treatment 02/2006
1	Patient Care 03/2005
1	Hip Replacement Arthroplasty (Total Hip Replacement) 11/2001
1	Physical Therapy Modalities (Physical Therapy Technique) 10/2001
1	Exercise Therapy (Therapy, Exercise) 10/2001